• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer.

作者信息

Gainor Justin F

机构信息

Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.

出版信息

J Thorac Dis. 2018 Jan;10(1):25-29. doi: 10.21037/jtd.2017.12.23.

DOI:10.21037/jtd.2017.12.23
PMID:29600014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5863154/
Abstract
摘要

相似文献

1
Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer.方枘圆凿？表皮生长因子受体突变的非小细胞肺癌中的程序性死亡-1抑制剂
J Thorac Dis. 2018 Jan;10(1):25-29. doi: 10.21037/jtd.2017.12.23.
2
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).表皮生长因子受体（EGFR）通路、Yes 相关蛋白（YAP）与非小细胞肺癌（NSCLC）中程序性死亡配体 1（PD-L1）的调控。
Int J Mol Sci. 2019 Aug 5;20(15):3821. doi: 10.3390/ijms20153821.
3
Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.表皮生长因子受体突变型非小细胞肺癌的免疫检查点抑制剂：当前的争议和未来的方向。
Lung Cancer. 2018 Jan;115:12-20. doi: 10.1016/j.lungcan.2017.11.009. Epub 2017 Nov 13.
4
[The expression of programmed death receptor 1 in non-small cell lung cancer and its clinicopathological features and prognosis showed a connection with epidermal growth factor receptor gene mutations].程序性死亡受体1在非小细胞肺癌中的表达及其临床病理特征和预后与表皮生长因子受体基因突变存在关联
Zhonghua Zhong Liu Za Zhi. 2017 Jun 23;39(6):419-423. doi: 10.3760/cma.j.issn.0253-3766.2017.06.004.
5
Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.表皮生长因子受体（EGFR）突变的非小细胞肺癌中程序性死亡配体1的表达及T790M状态
Lung Cancer. 2017 Sep;111:182-189. doi: 10.1016/j.lungcan.2017.07.022. Epub 2017 Jul 20.
6
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.用于表皮生长因子受体基因突变阳性非小细胞肺癌的酪氨酸激酶抑制剂：治疗学最新进展
J Oncol Pharm Pract. 2016 Jun;22(3):461-76. doi: 10.1177/1078155215577810. Epub 2015 Apr 8.
7
Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.表皮生长因子受体基因表达水平对接受一线表皮生长因子受体-酪氨酸激酶抑制剂治疗的表皮生长因子受体突变型肺腺癌患者临床结局的影响。
Tumour Biol. 2017 Mar;39(3):1010428317695939. doi: 10.1177/1010428317695939.
8
[Immunotherapy in Epidermal Growth Factor Receptor-mutant 
Non-small Cell Lung Cancer].[表皮生长因子受体突变的非小细胞肺癌中的免疫治疗]
Zhongguo Fei Ai Za Zhi. 2019 Aug 20;22(8):541-545. doi: 10.3779/j.issn.1009-3419.2019.08.11.
9
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.程序性死亡配体 1 表达、免疫微环境与表皮生长因子受体突变型肺腺癌患者接受酪氨酸激酶抑制剂治疗的临床结局的相关性。
Eur J Cancer. 2020 Jan;124:110-122. doi: 10.1016/j.ejca.2019.10.019. Epub 2019 Nov 21.
10
Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.临床参数和全身炎症状态对表皮生长因子受体突变的非小细胞肺癌患者再次使用表皮生长因子受体酪氨酸激酶抑制剂的影响。
BMC Cancer. 2016 Nov 8;16(1):868. doi: 10.1186/s12885-016-2917-6.

引用本文的文献

1
Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment.肿瘤坏死因子在肺癌中的作用：生物学复杂性及治疗抵抗。
Neoplasia. 2021 Feb;23(2):189-196. doi: 10.1016/j.neo.2020.12.006. Epub 2020 Dec 26.
2
Immunotherapy strategy of EGFR mutant lung cancer.表皮生长因子受体（EGFR）突变型肺癌的免疫治疗策略
Am J Cancer Res. 2018 Oct 1;8(10):2106-2115. eCollection 2018.

本文引用的文献

1
Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: A case report.奥希替尼诱发的间质性肺病在一名接受过纳武单抗预处理的非小细胞肺癌患者中的病例报告
Mol Clin Oncol. 2017 Sep;7(3):383-385. doi: 10.3892/mco.2017.1349. Epub 2017 Jul 25.
2
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial.奥希替尼对生物标志物表达的调控：AURA Ⅰ期试验配对肿瘤活检队列的结果。
J Thorac Oncol. 2017 Oct;12(10):1588-1594. doi: 10.1016/j.jtho.2017.07.011. Epub 2017 Jul 24.
3
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.一线纳武利尤单抗用于IV期或复发性非小细胞肺癌
N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.
4
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.基于 EGFR-TKI 治疗后疾病进展时 T790M 状态的肿瘤免疫微环境和纳武利尤单抗在 EGFR 突变阳性非小细胞肺癌中的疗效。
Ann Oncol. 2017 Jul 1;28(7):1532-1539. doi: 10.1093/annonc/mdx183.
5
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
6
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.纳武利尤单抗联合伊匹木单抗作为晚期非小细胞肺癌的一线治疗方案（CheckMate 012）：一项开放标签的1期多队列研究结果
Lancet Oncol. 2017 Jan;18(1):31-41. doi: 10.1016/S1470-2045(16)30624-6. Epub 2016 Dec 5.
7
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.《转移性 EGFR 突变非小细胞肺癌中免疫检查点抑制剂的Meta 分析》
J Thorac Oncol. 2017 Feb;12(2):403-407. doi: 10.1016/j.jtho.2016.10.007. Epub 2016 Oct 17.
8
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.卡铂和培美曲塞联合或不联合帕博利珠单抗用于晚期非鳞状非小细胞肺癌：开放标签KEYNOTE-021研究的随机2期队列研究
Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.
9
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
10
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.表皮生长因子受体（EGFR）突变和间变性淋巴瘤激酶（ALK）重排与非小细胞肺癌中PD-1通路阻断的低反应率相关：一项回顾性分析
Clin Cancer Res. 2016 Sep 15;22(18):4585-93. doi: 10.1158/1078-0432.CCR-15-3101. Epub 2016 May 25.